'It's a Crazy Mess': Interview With Pfizer Trial Whistleblower Exposing Vaxx Data Integrity Issues

“The day that I made the complaint to the FDA, a few hours later I was fired under the pretext that I was not a good fit. I'm 100% confident that I was not a good fit because I was refusing to be complicit in the fraud.” - Brook Jackson, former regional director for Ventavia Research Group, Pfizer clinical trial oversight

In this eye-opening interview with Ryan Cristian on The Last American Vagabond on December 1, Pfizer trial whistleblower Brook Jackson tells her story which was first documented by the British Medical Journal last month, breaks down the trial fraud she personally witnessed during her short time employed as a part of Pfizer's clinical 'vaccine' trial, and shares the evidence she collected documenting the plethora of data integrity issues that appear to have been part and parcel of this sham trial. As the BMJ piece written by investigative journalist Paul Thacker explains, concerning this rushed injection in light of the testimony of several researchers including Jackson, “speed may have come at the cost of data integrity and patient safety.”

Brook Jackson has spent nearly 20 years in the industry and is experienced in clinical trial oversight, and explains that within days of being hired to help oversee the trial research at a center in Texas, she was seeing problems the likes of which she had never witnessed in her entire career, and on a scale she found deeply disturbing and indicative of widespread fraud. The first problem she noticed was a clear lack of informed consent among trial participants being recruited, as well as a numbe of consent forms that appeared to contain forged signatures. Standard protocols were being ignored left and right, patients were not being properly monitered for adverse reactions following injection, follow up of reported adverse reactions was slow and in some cases apparently even nonexistant, participants were unblinded in a 'blinded' trial, used needles were being improperly discarded and left in open trash bags. and a host of other issued, all documented, were also witnessed and reported. Apart from photos, audio recordings and other documents provided by Jackson, the BMJ confirmed that problems indicative of fraud were witnessed by additional employees.

After repeatedly notifying Ventavia of these protocol violations and her concerns falling on deaf ears, she eventually notified the FDA via phone and detailed her concerns in an email the same day, as it would fall in their jurisdiction as regulatory oversight committee to investigate complaints related to data integrity issues and safety protocol violations. But instead of investigating her claims, it seems the FDA immediately notified either Pfizer or Ventavia, as she was fired within hours of filing her complaint, and no one apart from the FDA was privy to the fact she had contacted them with her concerns that day. If there was any doubt that the government agency was captured by the pharmaceutical industry, this clear neglect of duty by the FDA should put those doubts to rest.

Upon being fired, realizing the depth of the corruption she had been witness to, and seeing the clear politicization of the corporate media, Brook decided to take her story to the British Medical Journal, which she held in high esteem as one of the most highly regarded medical journals on the planet, rather than going to the media. She was then put into contact with Paul Thacker who she provided with her evidence and testimony, and the journal then spent months diligently vetting her story before publishing the bombshell piece on November 2 - Covid-19: Researcher blows the whistle on data integrity issues in Pfizer’s vaccine trial. As Thacker reported, Jackson revealed that “the company falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in Pfizer’s pivotal phase III trial.” Additionally, “Staff who conducted quality control checks were overwhelmed by the volume of problems they were finding.”

In a recording of a meeting in late September2020 between Jackson and two directors a Ventavia executive can be heard explaining that the company wasn’t able to quantify the types and number of errors they were finding when examining the trial paperwork for quality control. “In my mind, it’s something new every day,” a Ventavia executive says. “We know that it’s significant.”

The problems, listed in Jackson's email to the FDA and reported by the BMJ, also included:

• Participants placed in a hallway after injection and not being monitored by clinical staff
  Lack of timely follow-up of patients who experienced adverse events
  Protocol deviations not being reported
  Vaccines not being stored at proper temperatures
  Mislabelled laboratory specimens, and
  Targeting of Ventavia staff for reporting these types of problems.

Brook goes into much more detail than the BMJ in this interview and also covers a few problems that weren't discussed in the journal's investigative piece. All of the evidence obtained by the BMJ was also provided to The Last American Vagabond, and is now available for the public to view at the following link: https://www.thelastamericanvagabond.com/brook-jackson-interview-pfizer-whistleblower-exposes-cover-up-calling-vaccine-data-into-question/

Additionally, two other employees spoke with the BMJ, confirming Jackson's claims.

Two former Ventavia employees spoke to The BMJ anonymously for fear of reprisal and loss of job prospects in the tightly knit research community. Both confirmed broad aspects of Jackson’s complaint. One said that she had worked on over four dozen clinical trials in her career, including many large trials, but had never experienced such a “helter skelter” work environment as with Ventavia on Pfizer’s trial.
“I’ve never had to do what they were asking me to do, ever,” she told The BMJ. “It just seemed like something a little different from normal—the things that were allowed and expected.”
She added that during her time at Ventavia the company expected a federal audit but that this never came.
After Jackson left the company problems persisted at Ventavia, this employee said. In several cases Ventavia lacked enough employees to swab all trial participants who reported covid-like symptoms, to test for infection. Laboratory confirmed symptomatic covid-19 was the trial’s primary endpoint, the employee noted. (An FDA review memorandum released in August this year states that across the full trial swabs were not taken from 477 people with suspected cases of symptomatic covid-19.)
“I don’t think it was good clean data,” the employee said of the data Ventavia generated for the Pfizer trial. “It’s a crazy mess.”
A second employee also described an environment at Ventavia unlike any she had experienced in her 20 years doing research. She told The BMJ that, shortly after Ventavia fired Jackson, Pfizer was notified of problems at Ventavia with the vaccine trial and that an audit took place.

Despite the corporate media propaganda taking aim at this story and Ventavia actually going so far as to deny that Jackson had ever worked for them in a clear attempt to discredit her claims, Rebecca Coombes, Head of Journalism at The BMJ, wrote a rapid response standing by the journal's publishing of the piece and dispelling the lies being used in an attempt to discredit this bombshell story. After all, Jackson's claims were fully vetted and independently confirmed, and the BMJ piece externally peer-reviewed before publishing, while Ventavia's desperate attempt to discredit Jackson was a blatant lie, easily disproven with employment documents clearly listing Brook Jackson as one of several employees hired to oversee the Pfizer trial research. Media claims that the BMJ did not contact Ventavia or Pfizer for comment are also lies, and it is in fact Pfizer and Ventavia that have failed to clarify matters in their responses to the journal.

Meanwhile, the FDA failed to inspect any of Ventavia's sites following Jackson's report as they are ethically bound as a regulatory agency to do. An FDA spokesman told the BMJ that, “FDA has full confidence in the data that were used to support the Pfizer-BioNTech COVID-19 Vaccine authorization and the Comirnaty approval,” and an official statement on the alleged investigation into the reported problems by Pfizer likewise insists that: “Pfizer’s investigation did not identify any issues or concerns that would invalidate the data or jeopardize the integrity of the study.” Somehow I highly doubt that this is the case. Indeed, all of the available evidence indicates otherwise. It seems, as Brook Jackson is convinced, that not only does Pfizer's trial data have some seriously concerning integrity issues, but that the entire clinical 'trial' was one massive criminal fraud.